Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday. Other analysts also recently issued reports about the company. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from $128.00 to $121.00 and […]
Related Keywords
Canada , Garya Lyons , Raymond James , Robertw Baird , Neurocrine Biosciences , Darin Lippoldt , Ea Series , Neurocrine Biosciences Inc , Royal Bank , Guggenheim Capital , Bessemer Group Inc , Archer Investment Corp , Get Free Report , Director Gary , Wealth Management , Investment Corp , Bessemer Group , Neurocrine Biosciences Daily , Nasdaq Nbix , Nbix , Medical , 64125c10 , Upgrade , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.